Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SolastoTSE:6197 +0.54%48 EV-to-EBIT is 16.20 as of Sep. 07, 2026, which is 3% below its 10-year median of 16.66. GuruFocus rates TSE:6197 with a GF Score™ of 48/100 and a GF Value™ of 円567.65 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 474 Healthcare Providers & Services companies, Solasto ranks worse than 53.59% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Solasto's Enterprise Value is 円107,140 Mil.
Solasto's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円6,614 Mil. Therefore, Solasto's EV-to-EBIT for today is 16.20.
The historical rank and industry rank for Solasto's EV-to-EBIT or its related term are showing as below:
TSE:6197'
s EV-to-EBIT Range Over the Past 10 Years
Min: 6.36 Med: 16.66 Max: 31.83
Current: 16.2
During the past 11 years, the highest EV-to-EBIT of Solasto was 31.83. The lowest was 6.36. And the median was 16.66.
TSE:6197's EV-to-EBIT is ranked worse than 53.59% of 474
companies
in the Healthcare Providers & Services industry
Industry Median: 15.53
vs TSE:6197: 16.20
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Solasto's Enterprise Value for the quarter that ended in Mar. 2026 was 円106,868 Mil.
Solasto's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円6,614 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solasto EV-to-EBIT Related Terms
Solasto EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Solasto's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Solasto's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solasto EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Solasto's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Solasto's EV-to-EBIT falls into.
Solasto's current Enterprise Value is 円107,140 Mil.
Solasto's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円6,614 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solasto (TSE:6197) has a EV-to-EBIT of 16.20 as of Sep. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Solasto and its competitors. This is near median its historical median of 16.66. Over the past decade, Solasto's EV-to-EBIT has ranged from 6.36 to 31.83. According to the industry distribution chart, Solasto ranks #254 out of 474 companies in the Healthcare Providers & Services industry, placing it in the top 53.6%.
Is Solasto's EV-to-EBIT too high?
Solasto's current EV-to-EBIT of 16.20 is near median its 10-year median of 16.66. Over the past 10 years, this metric has ranged from a low of 6.36 to a high of 31.83. The Healthcare Providers & Services industry median EV-to-EBIT is 15.53. Solasto's value of 16.20 is 4.3% above this industry median. Based on the distribution chart, Solasto ranks #254 out of 474 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Solasto has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Solasto's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Solasto ranks #254 out of 474 companies for EV-to-EBIT. This places Solasto in the lower half of its industry. The industry median EV-to-EBIT is 15.53. Solasto's value of 16.20 is 4.3% above this benchmark. Historically, Solasto's own EV-to-EBIT has ranged from 6.36 to 31.83 over the past decade. While the company's 10-year median is 16.66 vs. the industry median of 15.53, Solasto has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.53, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solasto's current EV-to-EBIT of 16.20 is 4.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Solasto and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solasto's current EV-to-EBIT is 16.20, which is near median its own 10-year median of 16.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasto stock overvalued right now?
Based on GuruFocus' analysis, Solasto (TSE:6197) is currently considered Significantly Overvalued. The stock's GF Value™ is 円567.65, compared to a current price of 円1,118.00 — trading 97% above its estimated fair value. The current EV-to-EBIT is 16.20, which is near median its 10-year median of 16.66 and 4.3% above the Healthcare Providers & Services industry median of 15.53. Solasto's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Solasto (TSE:6197), the current EV-to-EBIT is 16.20 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solasto (TSE:6197) Overvalued in 2026?
Based on GuruFocus' analysis, Solasto stock appears to be overvalued.
The current stock price of 円1,118.00 is trading 97% above its estimated GF Value™ of 円567.65.
GuruFocus considers Solasto to be Significantly Overvalued.
Key valuation signals for TSE:6197:
EV-to-EBIT: 16.20 (near median its 10-year median of 16.66)
GF Value™: 円567.65 vs. price of 円1,118.00 (97% above fair value)
Industry Position: 4.3% above the Healthcare Providers & Services median (#254 of 474)
No single metric tells the full story. See the TSE:6197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6197 has been successfully added to your 
